Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763121 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
A Phase 3 study, sponsored by Areteia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,061
- Enrollment target
NCT05763121 is a Phase 3 study that was terminated before completion, run by Areteia Therapeutics. The registered enrollment target is 1,061 participants.
The verdict
NCT05763121, a Phase 3 study, was terminated before completion, sponsored by Areteia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,061 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Interventions
- DRUG Placebo
- DRUG Dexpramipexole Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,061 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763121
The ClinicalTrials.gov registry entry for NCT05763121 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,061 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Areteia Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05763121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05763121 about?
NCT05763121 is a clinical study titled "A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.". This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
What is the current status of trial NCT05763121?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,061 participants. The study started on 2023-01-30. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT05763121?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT05763121?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.